Association between autoantibodies and interstitial lung disease in autoimmune disease patients: a retrospective study
Authors' conclusion
Anti-Ro52, together with age and anti-MDA5, was identified as a significant predictor of ILD in IIM patients.
Study context
- Population
- Autoimmune diseases (AID) patients who underwent antinuclear antibody (ANA) testing between 2017 and 2019, Peking Union Medical College Hospital
- Participants
- 2,021 patients
- Exposure
- AID patients with vs without interstitial lung disease (ILD), by autoantibody profile
- Outcome
- Association between specific autoantibodies, particularly anti-Ro52, and ILD in AID
Methodological detailssingle-centre, least absolute shrinkage and selection operator (LASSO) regression
- Single-centre
- LASSO regression
Main finding
As reported in the abstract
Anti-Ro52 frequency in IIM
P < 0.0001
Observational data: associations, not effects.
Further findings
ILD prevalence across AID subgroups
- Highest rates in idiopathic inflammatory myopathies (IIM), overlap syndrome and SSc
Anti-RNP in lupus-ILD
- Anti-RNP detected at a significantly higher rate in lupus-ILD patients
Anti-SSA/Ro60 (Sjögren's disease) and anti-CENP B (SSc)
- Positivity inversely associated with ILD
ILD progression in MCTD
- Anti-Ro52 positivity associated with a more than two-fold increased risk of ILD progression
Original publication
Association between autoantibodies and interstitial lung disease in autoimmune disease patients: a retrospective study. Clin Exp Rheumatol. Published 8 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →